All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

New agents in the MF therapeutic landscape

May 8, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

During the MPN Hub Steering Committee meeting, we invited Steffen Koschmieder, Uniklinikum RWTH Aachen, Aachen, DE, to give a presentation and chair a discussion on new agents in the myelofibrosis (MF) therapeutic landscape. MPN Hub Steering Committee members Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Tiziano Barbui, and Laura Michaelis joined the discussion.

New agents in the MF therapeutic landscape

In this video, Steffen Koschmieder discusses recent clinical trials in MF, including MOMENTUM, BOREAS, IMpactMF, MANIFEST-2, TRANSFORM-1, LIMBER-313, and INDEPENDENCE. Koschmieder details the study designs and endpoints, as well as results data available to date. The committee members discuss data from each trial and the potential implications for the management of MF.

Your opinion matters

How would you define myelofibrosis treatment failure? A. A lack of spleen reduction B. A lack of symptom reduction C. A lack of either spleen or symptom reduction D. Symptom relief deemed inadequate by the patient
2 votes - 15 days left ...


Subscribe to get the best content related to MPN delivered to your inbox